Integra's Win May Give Cause For Re-Evaluation Of Future Exploratory Research Activities
By
Pillsbury Winthrop Shaw Pittman LLP
In the wake of Integra Lifesciences I, Ltd. v. Merck kGaA, companies should consider re-examining their use of patented technology in pre-clinical Research and Development activities. It is critical that companies and their advisors review their Research and Development activities to be certain they are objectively within the scope of permitted investigations under ? 271(e)(1).
|